Loading
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
Latest quote
¥54.00
+¥1.00 · +1.89%
Regular session · JST · Market data may be delayed.
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
Regular session · JST · Market data may be delayed.
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 314K JPY | 6.13M JPY | 530K JPY | 1.07M JPY | 126.87M JPY |
| Cost of goods sold | 41.89M JPY | 43.99M JPY | 43.56M JPY | 13.91M JPY | 1.75M JPY |
| Gross profit | −41.58M JPY | −37.86M JPY | −43.03M JPY | −12.84M JPY | 125.12M JPY |
| Research and development | 1.3B JPY | 537.99M JPY | 677.45M JPY | 908.68M JPY | 662.11M JPY |
| Selling, general, and administrative | 311.07M JPY | 295.47M JPY | 256.13M JPY | 247.55M JPY | 208.05M JPY |
| Operating expenses | 1.61B JPY | 863.9M JPY | 951.07M JPY | 1.16B JPY | 870.16M JPY |
| Interest income | 3.28M JPY | 170K JPY | 23K JPY | 29K JPY | 31K JPY |
| Depreciation and amortization | 41.89M JPY | 42.53M JPY | 43.56M JPY | 13.91M JPY | 1.37M JPY |
| Operating income | −1.65B JPY | −901.76M JPY | −994.11M JPY | −1.17B JPY | −745.04M JPY |
| Net income | −1.91B JPY | −889.09M JPY | −933.42M JPY | −1.17B JPY | −682.27M JPY |
Company facts updated Sep 9, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
